Efficacy and safety of roxadustat for anaemia in dialysis‐dependent and non‐dialysis‐dependent chronic kidney disease patients: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Efficacy and safety of roxadustat for anaemia in dialysis‐dependent and non‐dialysis‐dependent chronic kidney disease patients: A systematic review and meta‐analysis

Published:2021-09-30 Issue: Volume: Page:
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Zheng Li¹²^ORCID,Tian Jinhui¹^ORCID,Liu Deping³^ORCID,Zhao Yan²,Fang Xiaoyong²,Zhang Yatong⁴,Liu Yuming⁵

Affiliation:

1. Evidence‐Based Medicine Center, School of Basic Medical Sciences Lanzhou University Lanzhou China

2. Department of Pharmacy China Aerospace Science & Industry Corporation 731 Hospital Beijing China

3. Department of Cardiovascular Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine Chinese Academy of Medical Sciences Beijing China

4. Department of Pharmacy Beijing Hospital Beijing China

5. Department of Endocrinology and Metabolism and Nephropathy China Aerospace Science & Industry Corporation 731 Hospital Beijing China

Funder

National Key Research and Development Program of China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15055

Reference41 articles.

1. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease